Pfizer’s Talzenna cleared for breast cancer
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Read More
Tag: EMBRACA
Pfizer files PARP inhibitor for breast cancer in US, EU
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
Read More
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
- eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration
- Miranda Dini launches GOLD amid industry shifts
